Pharma Deals Review, Vol 2007, No 88 (2007)

Font Size:  Small  Medium  Large

Sepracor’s Insomnia Drug Enters Europe with GSK Deal

Business Review Editor

Abstract


Sepracor out-licensed the commercialization rights for insomnia product Lunivia® to GlaxoSmithKline (GSK) which will market the product worldwide excluding US, Canada, Mexico and Japan. The deal is worth up to US$ 175 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.